Vanguard Group
ORIC icon

Vanguard Group’s Oric Pharmaceuticals ORIC Stock Holding History

Vanguard Group’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$37.2M Sell
4,541,974
-108,164
-2% -$1.25M ﹤0.01% 2327
2025
Q3 		$55.8M Buy
4,650,138
+1,525,445
+49% +$16M ﹤0.01% 2105
2025
Q2 		$31.7M Sell
3,124,693
-91,194
-3% -$612K ﹤0.01% 2334
2025
Q1 		$17.9M Buy
3,215,887
+12,098
+0.4% +$106K ﹤0.01% 2558
2024
Q4 		$25.9M Buy
3,203,789
+36,478
+1% +$335K ﹤0.01% 2462
2024
Q3 		$32.5M Sell
3,167,311
-32,415
-1% -$320K ﹤0.01% 2369
2024
Q2 		$22.6M Buy
3,199,726
+317,671
+11% +$2.84M ﹤0.01% 2511
2024
Q1 		$39.6M Buy
2,882,055
+629,536
+28% +$7.48M ﹤0.01% 2268
2023
Q4 		$20.7M Sell
2,252,519
-336,350
-13% -$2.43M ﹤0.01% 2581
2023
Q3 		$15.7M Buy
2,588,869
+791,843
+44% +$6.49M ﹤0.01% 2651
2023
Q2 		$13.9M Buy
1,797,026
+153,952
+9% +$874K ﹤0.01% 2763
2023
Q1 		$9.37M Buy
1,643,074
+96,789
+6% +$506K ﹤0.01% 2971
2022
Q4 		$9.11M Buy
1,546,285
+199,423
+15% +$673K ﹤0.01% 2993
2022
Q3 		$4.31M Sell
1,346,862
-66,869
-5% -$268K ﹤0.01% 3400
2022
Q2 		$6.33M Sell
1,413,731
-230,288
-14% -$919K ﹤0.01% 3244
2022
Q1 		$8.78M Buy
1,644,019
+13,981
+0.9% +$126K ﹤0.01% 3222
2021
Q4 		$24M Buy
1,630,038
+31,116
+2% +$485K ﹤0.01% 2744
2021
Q3 		$33.4M Buy
1,598,922
+365,052
+30% +$7.4M ﹤0.01% 2587
2021
Q2 		$21.8M Sell
1,233,870
-21,337
-2% -$468K ﹤0.01% 2791
2021
Q1 		$30.8M Buy
1,255,207
+387,656
+45% +$12.3M ﹤0.01% 2578
2020
Q4 		$29.4M Buy
867,551
+441,385
+104% +$12.7M ﹤0.01% 2463
2020
Q3 		$10.7M Sell
426,166
-2,548
-0.6% -$60.6K ﹤0.01% 2751
2020
Q2 		$14.5M Buy
+428,714
New +$13.7M ﹤0.01% 2582

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group's ORIC Position: Q4 2025 in Review

Vanguard Group reduced its Oric Pharmaceuticals (ORIC) stake by 2.3% in Q4 2025, selling an estimated $1.25M and leaving 4,541,974 shares worth $37.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2327.

Vanguard Group first reported a position in ORIC in Q2 2020 and has held it in 23 quarters since. The position peaked at $55.8M in Q3 2025. 164 funds tracked by Wall St. Rank hold ORIC as of Q4 2025.

  • Vanguard Group held 4,541,974 shares of Oric Pharmaceuticals worth $37.2M as of Q4 2025.
  • Vanguard Group sold 108,164 Oric Pharmaceuticals shares in Q4 2025, an estimated $1.25M.
  • Oric Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2327 holding.
  • Vanguard Group first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Vanguard Group's Oric Pharmaceuticals position peaked at $55.8M in Q3 2025.
  • 164 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.